In one small scale clinical trial of depressed patients, an improvement of symptoms which included anxiety, lack of drive and desire was observed.  In patients with dysthymia , unipolar , and bipolar depression significant improvement was observed.  In this series of studies, mesterolone lead to a significant decrease in luteinizing hormone and testosterone levels.  In another study, 100 mg mesterolone cipionate was administered twice monthly.  With regards to plasma testosterone levels, there was no difference between the treated versus untreated group, and baseline luteinizing hormone levels were minimally affected. 
DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.
The Mesterolone hormone is not estrogenic. It does not aromatize and it carries no progestin nature. As a result, the side effects of Proviron will not include any related effects such as gynecomastia or excess water retention. Such adverse effects are impossible with this steroid. This will also greatly reduce the risk of high blood pressure as high blood pressure associated with anabolic steroid use is often due to extreme water retention. In fact, Proviron should provide an anti-estrogenic effect by preventing testosterone to estrogen conversion or at least tremendously slow it down.